LM-108 antibody and sintilimab
2023LY0834
Phase 2 small_molecule active
Quick answer
LM-108 antibody and sintilimab for NSCLC is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active